Geographic Area
Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan
Gilead Sciences; Foster City; California; manufacturing facility; biopharmaceuticals; $32 billion investment; economic impact; expansion; R&D; job creation; U.S. manufacturing
Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)
cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth
Amgen to Invest Over $600M in New Innovation Centre at California Headquarters
Amgen; innovation centre; science and innovation hub; Thousand Oaks; California; biotechnology; construction; automation; digital tools; therapeutic development; tax incentives; capital investment
Teva Launches First Generic GLP-1 Weight-Loss Drug in the US
Teva; GLP-1; generic; weight loss; liraglutide; FDA approval; Saxenda; obesity treatment; United States
Genentech’s $700M North Carolina Plant and Telix’s FDA CRL Update
Genentech; Roche; North Carolina; manufacturing facility; $700 million; Holly Springs; metabolic medicines; obesity treatments; biomanufacturing; Telix; FDA; Complete Response Letter (CRL); imaging agent
Exelixis to Lay Off 130 Employees, Shut Down Pennsylvania Site in Post-Pandemic Downsizing
Exelixis; layoffs; Pennsylvania site closure; post-pandemic downsizing; biotech reorganization; Alameda headquarters; zanzalintinib; cabozantinib; King of Prussia
Exelixis Closes Pennsylvania Site, Cuts 130 Jobs in Major Restructuring
Exelixis; layoffs; Pennsylvania; King of Prussia; biotech; job cuts; site closure; restructuring; Alameda Headquarters; cancer drugs
Regeneron Reports Phase 3 Success for Cemdisiran in Rare Disease Generalized Myasthenia Gravis
Regeneron; Phase 3 trial; cemdisiran; generalized myasthenia gravis; rare disease; RNA drug; siRNA; Alnylam Pharmaceuticals; U.S. regulatory submission
Akeso Scores Two Wins in Phase 3 Trials, Tees Up Regulatory Submissions in China
Akeso; Phase 3 trials; gumokimab; manfidokimab; ankylosing spondylitis; atopic dermatitis; regulatory submission; China; autoimmune diseases; clinical trial results
Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times
pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves